Preliminary Evidence Supports Psilocybin’s Efficacy in Bipolar Depression

Preliminary results from a small clinical trial indicate that a single dose of synthetic psilocybin, combined with psychotherapy, could significantly alleviate treatment-resistant depression in individuals with bipolar II disorder (BDII). The study, involving 15 participants, showed that three weeks after the treatment, all participants experienced a significant reduction in depression scores, with 80% meeting criteria for both response and remission at the 12-week mark. Importantly, there were no reports of adverse effects such as mixed or manic symptoms, psychotic symptoms, or suicidal thoughts. While these findings seem promising, the study’s limited size and open-label design necessitate cautious interpretation. Lead investigator Scott Aaronson, MD, emphasizes the need for further clinical exploration of psychedelics’ potential in treating individuals with treatment-resistant bipolar II. This study challenges the historical exclusion of bipolar disorder patients from psilocybin research, suggesting a possible safety inclusion in future studies.